Because PI3Kδ and PKCβ are major isoforms in CLL cells and current targets in clinical trials [3, 5, 24, 25], we tested the effect of specifically blocking these isoforms in our system. Here, PRKCB is linked to B-cell chronic lymphocytic leukemia.